Trending Across touchONCOLOGY

At a glance: education, conference reports and articles

More From CME & Education

View All

Learn more from touchONCOLOGY with CME-accredited and independent learning activities

Breast Cancer, Genitourinary Cancers, Ovarian Cancer
CME ACCREDITED
touchCONGRESS
Antibody-drug conjugates for patients with solid tumours: Practical analysis of the latest data from ESMO 2020
Mikel Ross, MSN, RN Watch Time: 90 mins

Watch this two-part activity discussing the latest developments in antibody-drug conjugates for solid tumours. Filmed following presentations at ESMO 2020. Part 1: Watch internationally renowned expert Mikel Ross review key data from the congress Watch Now Part 2: Choose from leading experts who discuss what the latest data mean for global and regional practice Select An Interview

Learning objectives
Learning Objectives
  • Recognize the antibody drug conjugates (ADCs) that are available for the treatment of solid tumours
  • Summarize how emerging and evolving ADCs may improve outcomes for patients with solid tumours
  • Discuss practical strategies for the management of adverse events associated with approved ADCs for solid tumours
Lung Cancer
touchSATELLITE SYMPOSIUM
PD-1 inhibitors on the horizon for NSCLC: Current knowledge, future possibilities
Professor Tony Mok and Professor Giorgio Scagliotti Watch Time: 119 mins

Watch the footage from our Satellite Symposium at the ESMO Virtual Congress 2020, exploring novel PD-1 inhibitors on the horizon for NSCLC.

Learning objectives
Learning Objectives
  • Review the latest clinical and pre-clinical data for anti-PD-1 agents in NSCLC
  • Discuss how current and emerging anti-PD-1 agents may be incorporated into the treatment landscape for NSCLC
  • Summarize how to identify the patients most suitable for anti-PD-1 blockade

    • More From The Conference Hub

    View All

    View highlights and coverage from leading international Oncology congresses

    More From Learning Zone

    View All

    Medical education and communication on key topics in the area of Oncology. Content in this section is sponsored by the pharmaceutical industry.

    Renal Cancer
    touchEXPERT BRIEFING
    The Role of High-Dose IL-2 in mRCC today
    Dr Scott S. Tykodi, Dr Brendan Curti Watch Time: 17 mins

    Watch leading experts discuss recent developments in checkpoint inhibitor therapy to treat mRCC,5,6 and the findings from a recent analysis of the PROCLAIMSM registry.

    Learning objectives
    Learning Objectives
    • Understand the importance of clinical risk factors in the treatment and management of mRCC and be aware of the current NCCN recommendations.
    • Appreciate the clinical benefits and safety profile, including risks, of high-dose interleukin-2 therapy and how these may guide treatment decisions dependent on clinical risk factors.
    • Demonstrate an awareness of the results of the CheckMate 214 study, showing differing survival and clinical response outcomes in patients with mRCC receiving checkpoint inhibitor therapy dependent on disease risk category.
    • Understand the latest results from the PROCLAIMSM database, showing consistent survival benefits with high-dose interleukin-2 therapy across favorable, intermediate and poor-risk mRCC patients.
    • Appreciate how these recent findings might alter the treatment paradigm for mRCC.
    Renal Cancer
    touchINSIGHT
    First-line Treatment Options for Renal Cell Carcinoma
    Dr Ulka Vaishampayan Watch Time: 10 mins

    Dr Ulka Vaishampayan, from Karmanos Cancer Institute, Wayne State University, MI, USA, discusses first-line treatment options for renal cell carcinoma, including the promising findings from the PROCLAIM registry, which suggest that high dose interleukin-2 is safe and effective before targeted therapy and immune checkpoint blockade.

    Latest Journal Articles

    View All

    Read the latest articles from our peer reviewed Oncology journals published by touchONCOLOGY

    Gastrointestinal Oncology
    FOREWORD – EUROPEAN ONCOLOGY & HAEMATOLOGY – VOLUME 16 ISSUE 1 – SUMMER 2020
    Axel Merseburger

    European Oncology & Haematology. 2020;16(1):11

    Welcome to the summer edition of European Oncology & Haematology. The COVID-19 pandemic has had a devastating impact on cancer and other illness care. In addition to the heightened susceptibility of patients with cancer to infections, lockdown has resulted in delayed screening and reduced treatment of early-stage disease. However, things are starting to move in the […]

    Prostate Cancer
    Immunotherapy in Advanced Prostate Cancer
    Manreet Randhawa, Robert Jones

    European Oncology & Haematology. 2020;16(1):44–50 DOI: https://doi.org/10.17925/EOH.2020.16.1.44

    Prostate cancer is the second most common cause of cancer mortality in men, with most deaths occurring as a result of metastatic disease that has become resistant to androgen deprivation therapy (ADT).1 Most recently, immunotherapy, in the form of immune checkpoint inhibitors, has been successful in the treatment of a variety of advanced common solid tumours, […]

    Lung Cancer
    Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy
    Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli

    European Oncology & Haematology. 2020;16(1):39-43 DOI: https://doi.org/10.17925/EOH.2020.16.1.39

    Historically, chemotherapy represented the only available treatment for patients with advanced non-small-cell lung cancer (NSCLC) who did not show any target molecular driver, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) or the receptor tyrosine kinase ROS1. Unfortunately, limited efficacy was reported using chemotherapy alone.1 The advent of immunotherapy, a treatment based on […]

    Lung Cancer
    ALK Inhibitors in ALK-positive NSCLC with Central Nervous System Metastases
    Mihaela Aldea, Benjamin Besse, Lizza EL Hendriks

    European Oncology & Haematology. 2020;16(1):18-21 DOI: https://doi.org/10.17925/EOH.2020.16.1.18

    At initial diagnosis of metastatic disease, central nervous system (CNS) metastases are present in 22–33% of patients with anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC). After crizotinib failure, the incidence can reach up to 70%, compared with 40% in all comers.1 The presence of CNS disease is an indicator of poor prognosis in […]

    Want To Know More About Our Journals?

    Taking a balanced and practical view of the current clinical landscape in Oncology is at the heart of touchONCOLOGY and the journals we produce.

    The European Oncology & Haematology and Oncology & Hematology Review (US) are free-to-access, peer reviewed journals that aim to provide balanced and objective articles relevant to the day-to-day clinical setting.

    Learn more about our journals

    Society & Congress Partners

    View All

    touchONCOLOGY is proud to partner with leading medical societies and congresses from around the world to bring you news and insight from virtual and live events
    Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar